Company Overview

Artelo Biosciences, Inc. is a U.S.-based clinical-stage biotechnology company focused on the development of therapeutics that modulate lipid-signaling pathways, particularly the endocannabinoid system. The company operates within the biotechnology and pharmaceutical industries, with research programs targeting cancer supportive care, oncology, anxiety-related disorders, inflammation, and metabolic diseases. Artelo’s core strategy centers on developing proprietary small molecules and biologic compounds designed to address conditions with significant unmet medical need.

The company’s primary pipeline includes ART27.13, a fatty acid binding protein inhibitor being evaluated for cancer-associated anorexia and cachexia; ART26.12, a selective cannabinoid receptor agonist program focused on anxiety and post-traumatic stress-related indications; and ART12.11, a cocrystal cannabidiol formulation platform. Artelo originated from a corporate restructuring and rebranding of Reactive Medical, Inc., later operating as Cellectar Biosciences’ spinout-related entity before adopting its current name in 2018. Its positioning is differentiated by its concentration on cannabinoid science and lipid-signaling therapeutics supported by intellectual property portfolios and specialized drug development expertise.

Business Operations

Artelo conducts operations primarily through research and development activities rather than commercial product sales, as it remains a clinical-stage enterprise without approved marketed therapies. Revenue generation historically has been limited and has largely consisted of financing activities, licensing arrangements, and potential collaboration-related income rather than recurring commercial revenue. The company’s operational focus is concentrated in its therapeutic development programs, particularly ART27.13 and ART26.12, which represent its principal clinical and preclinical assets.

The company operates mainly in the United States, while also utilizing international contract research organizations, manufacturing partners, and clinical trial service providers. Artelo relies on outsourced development infrastructure for laboratory research, formulation development, regulatory support, and clinical operations. The company maintains intellectual property rights associated with cannabinoid receptor modulation, FABP inhibition, and pharmaceutical compositions related to its drug candidates. Public filings identify collaborations and licensing relationships supporting compound development and patent access, although the company does not currently report large-scale joint ventures or majority-owned operating subsidiaries comparable to larger pharmaceutical peers.

Strategic Position & Investments

Artelo’s strategic direction is centered on advancing differentiated cannabinoid and lipid-signaling therapies through clinical development while preserving capital efficiency typical of emerging biotechnology firms. The company has prioritized indications where existing treatment options remain limited, particularly cancer cachexia and anxiety-related disorders. Its development strategy includes pursuing orphan or specialty therapeutic opportunities that may benefit from streamlined regulatory pathways and targeted commercialization models.

A significant component of Artelo’s investment strategy involves continued funding of proprietary compound development and intellectual property expansion. The company has invested in advancing ART27.13 through clinical-stage evaluation and in expanding the utility of its cannabinoid receptor technologies. Artelo has also pursued formulation-related innovations through ART12.11, designed to improve pharmaceutical delivery and bioavailability characteristics associated with cannabidiol-based therapies. Public disclosures indicate ongoing evaluation of partnership opportunities and external financing to support pipeline advancement, though large transformative acquisitions have not been publicly reported.

Geographic Footprint

Artelo Biosciences is headquartered in Solana Beach, California, and its operational footprint is primarily concentrated in the United States. Despite its relatively small scale, the company maintains international engagement through global research vendors, patent filings, manufacturing relationships, and clinical development activities. Its intellectual property portfolio includes protections extending into multiple international jurisdictions.

The company’s market and research relevance extends into North America and parts of Europe, particularly in areas involving cannabinoid therapeutics and oncology supportive care research. While Artelo does not maintain extensive international commercial infrastructure, it participates in globally relevant therapeutic sectors and utilizes cross-border scientific and regulatory partnerships common among clinical-stage biotechnology companies.

Leadership & Governance

Artelo Biosciences is led by executives with backgrounds in biotechnology commercialization, pharmaceutical development, finance, and cannabinoid science. Leadership has emphasized disciplined capital allocation, targeted clinical advancement, and the development of proprietary therapies addressing unmet medical needs. The company’s governance structure follows public-company standards applicable to Nasdaq-listed biotechnology firms and is guided through board oversight and SEC reporting obligations, including disclosures contained in SEC filings such as annual reports and proxy statements.

Key executives and leadership include:

• Gregory D. Gorgas – Chief Executive Officer and Director
• Brian A. McNeill – Chief Financial Officer
• Steven D. Reich, Ph.D. – Chief Scientific Officer
• Andrew Yates, Ph.D. – Senior Vice President and Chief Medical Officer

The company’s leadership strategy has consistently focused on advancing a specialized cannabinoid and lipid-signaling therapeutic platform while leveraging external partnerships, intellectual property development, and clinical milestone execution to support long-term growth objectives.